Saturday, September 30, 2023
Saturday, September 30, 2023

Contact us 561.316.3330

Access Vascular Receives FDA Clearance for HydroPICC® Biomaterial-Based Dual-Lumen Catheter

Access Vascular, Inc. (AVI) today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its HydroPICC® Dual-Lumen catheter.

Designed and constructed using the same proprietary hydrophilic biomaterial as AVI’s single-lumen HydroPICC® and HydroMID® catheters, these devices showed significant reduction in complications such as occlusions, replacements, Deep Vein Thrombosis and phlebitis in recent studies.

“We are proud to announce FDA clearance for our HydroPICC Dual-Lumen catheter as the latest addition to our family of devices,” said Access Vascular CEO James Biggins. “Hospital patients experience unnecessarily high incidences of vascular access complications, largely because of the material used by competitive catheters. With roughly half of all PICC usage in hospitals attributed to dual-lumen devices, the availability of our biomaterial-based dual-lumen catheter means even more patients can now benefit from uninterrupted treatment and less risk of complications.”

A majority of hospital patients receive a vascular access device and 30% of those patients encounter a vascular access-related complication. Most are caused by the materials used in standard catheters, which trigger the body’s natural defenses and causes the build-up of platelets – or thrombus, leading to complications such as phlebitis, blood clots and infections.

AVI’s patented hydrophilic biomaterial catheters mimic the body’s chemistry to dramatically reduce these common and costly complications. Given the high utilization and complication rates of standard catheters, the use of AVI devices can meaningfully improve patient outcomes.

A reduction in complications can also have a positive impact on hospital economics. A recent study on the single-lumen HydroPICC® demonstrated a statistically significant reduction in complications such as occlusions and replacements compared to traditional catheters, resulting in a 50% avoidance of additional material costs.1

Access Vascular advises the HydroPICC Dual-Lumen is a 5 French catheter available in multiple kit configurations. It will be made available over the coming weeks as the newest addition to the expanding family of AVI vascular access devices. AVI plans to continue expansion of its portfolio by adding more peripheral intravenous and central line options.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.


4SC Receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA

Jason Loveridge, Ph.D., CEO of 4SC, commented: “Receiving orphan drug designation for resminostat provides us with a number of important benefits, most crucially 7 years’ market exclusivity in the US, a key foundation of our efforts to commercialise Kinselby.  We are currently preparing a marketing authorisation application for Kinselby in the EU, which remains on track for submission in Q1 2024.”

Abyrx Receives FDA Clearance for MONTAGE ® Settable Bone Putty for Use in Cardiothoracic Surgery

By expanding the range of FDA-cleared surgical applications for MONTAGE, this latest milestone positions Abyrx to build upon the more than 25,000 units of MONTAGE that have been used to date by surgeons in trauma, orthopedics, sports medicine, foot and ankle, and craniomaxillofacial procedures.

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

By using this website you agree to accept Medical Device News Magazine Privacy Policy